Vericel Corporation (NASDAQ:VCEL) Receives Average Rating of “Moderate Buy” from Analysts

Vericel Corporation (NASDAQ:VCEL) has been given a consensus rating of “Moderate Buy” by the seven brokerages that are presently covering the company, Marketbeat reports. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $57.50.

A number of research firms have issued reports on VCEL. Truist Financial reduced their target price on shares of Vericel from $50.00 to $45.00 and set a “buy” rating on the stock in a report on Thursday, December 18th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Vericel in a research note on Monday, December 29th. Wall Street Zen lowered Vericel from a “buy” rating to a “hold” rating in a report on Saturday. Finally, Zacks Research downgraded Vericel from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 12th.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Russell Investments Group Ltd. lifted its stake in Vericel by 38.4% in the second quarter. Russell Investments Group Ltd. now owns 118,856 shares of the biotechnology company’s stock valued at $5,057,000 after buying an additional 32,976 shares during the last quarter. Frontier Capital Management Co. LLC increased its holdings in shares of Vericel by 74.3% in the 2nd quarter. Frontier Capital Management Co. LLC now owns 398,960 shares of the biotechnology company’s stock valued at $16,976,000 after acquiring an additional 170,006 shares during the period. Strs Ohio purchased a new stake in Vericel in the 1st quarter valued at $812,000. Voya Investment Management LLC boosted its stake in Vericel by 68.7% during the 1st quarter. Voya Investment Management LLC now owns 24,664 shares of the biotechnology company’s stock worth $1,101,000 after purchasing an additional 10,048 shares during the period. Finally, Congress Asset Management Co. grew its position in Vericel by 18.0% during the 2nd quarter. Congress Asset Management Co. now owns 1,742,324 shares of the biotechnology company’s stock worth $74,136,000 after purchasing an additional 265,606 shares during the last quarter.

Vericel Price Performance

Shares of Vericel stock opened at $37.40 on Friday. The stock has a market capitalization of $1.89 billion, a price-to-earnings ratio of 155.84 and a beta of 1.17. The business has a 50-day moving average of $38.09 and a 200 day moving average of $36.49. Vericel has a 12 month low of $29.24 and a 12 month high of $63.00.

Vericel (NASDAQ:VCEL) last issued its quarterly earnings results on Thursday, November 6th. The biotechnology company reported $0.10 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.02) by $0.12. Vericel had a net margin of 5.06% and a return on equity of 4.30%. The business had revenue of $67.50 million for the quarter, compared to analysts’ expectations of $64.57 million. The business’s quarterly revenue was up 16.6% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.02) earnings per share. Equities research analysts anticipate that Vericel will post 0.14 earnings per share for the current year.

Vericel Company Profile

Vericel Corporation is a biotechnology company specializing in the development, manufacturing and commercialization of cell-based therapies for patients with severe diseases and conditions. The company’s expertise lies in regenerative medicine, where it harnesses the power of autologous cell processing to create products designed to restore function and promote healing in damaged tissues.

Vericel currently markets two FDA-approved therapies. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is indicated for the repair of symptomatic cartilage defects of the knee in adult patients.